Profile data is unavailable for this security.
About the company
Oxford Nanopore Technologies plc is engaged in the generation of molecular sensing technology based on nanopores. The Company has developed a deoxyribonucleic (DNA)/ ribonucleic acid (RNA) sequencing technology. The Company’s segments include Life Science Research Tools, which offers products and services for research use, and COVID Testing, which provides products for SAR-Cov-2 testing. Its sequencing technology offers real-time analysis, in fully scalable formats from pocket to population scale, that can analyze native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths. Its products include MinION, GridION, PromethION, Flongle and others. MinION is a real-time device for DNA and RNA sequencing. GridION is a benchtop device designed to run and analyze up to five MinION or Flongle Flow Cells. Flongle is an adapter for MinION or GridION that enables direct, real-time DNA sequencing, or cDNA sequencing on smaller, single-use flow cells.
- Revenue in GBP (TTM)167.75m
- Net income in GBP-159.06m
- Incorporated2005
- Employees1.24k
- LocationOxford Nanopore Technologies PLCOxford Science ParkGosling Building, Edmund Halley RoadOXFORD OX4 4DQUnited KingdomGBR
- Websitehttps://www.nanoporetech.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Draegerwerk AG & Co KGaA | 2.81bn | 97.16m | 678.87m | 16.39k | 6.87 | 0.5549 | 3.09 | 0.242 | 6.20 | 6.20 | 179.19 | 76.78 | 1.12 | 2.54 | 5.02 | 205,867.60 | 3.91 | 3.26 | 5.80 | 4.87 | 43.62 | 44.16 | 3.50 | 3.05 | 1.13 | 6.57 | 0.2432 | 11.38 | 10.78 | 5.39 | 271.05 | 33.87 | 2.64 | 55.73 |
El En SpA | 550.58m | 41.53m | 688.21m | 2.03k | 17.42 | 2.42 | 13.16 | 1.25 | 0.6223 | 0.6223 | 8.25 | 4.49 | 0.9141 | 1.77 | 3.69 | 316,823.50 | 7.02 | 7.43 | 12.89 | 13.52 | 40.03 | 38.83 | 7.68 | 7.63 | 1.19 | -- | 0.1845 | -- | 2.78 | 14.88 | -12.47 | 23.49 | -13.40 | -- |
Medartis Holding AG | 195.95m | 3.59m | 697.16m | 829.00 | 189.12 | 2.91 | 30.63 | 3.56 | 0.3088 | 0.3088 | 17.04 | 20.07 | 0.5377 | 0.5674 | 4.96 | 265,720.50 | 0.9845 | 0.1919 | 1.13 | 0.2153 | 80.53 | 82.33 | 1.83 | 0.3542 | 3.15 | 4.03 | 0.3227 | 0.00 | 15.96 | 11.81 | 110.70 | -31.82 | 5.37 | -- |
Revenio Group Oyj | 80.69m | 15.87m | 765.42m | 216.00 | 48.22 | 9.25 | 39.95 | 9.49 | 0.7205 | 0.7205 | 3.66 | 3.76 | 0.7069 | 5.50 | 7.60 | 447,574.10 | 13.90 | 14.33 | 16.77 | 17.90 | 51.01 | 50.73 | 19.66 | 21.13 | 1.79 | 28.49 | 0.1521 | 55.81 | -0.4125 | 25.80 | -12.15 | 18.72 | 17.67 | 6.30 |
Arjo AB (publ) | 831.82m | 39.72m | 791.11m | 6.94k | 22.98 | 1.55 | 6.90 | 0.951 | 1.97 | 1.97 | 41.21 | 29.20 | 0.6957 | 4.40 | 6.51 | 1,651,221.00 | 3.31 | 3.55 | 4.51 | 5.55 | 43.68 | 44.01 | 4.76 | 5.41 | 0.6657 | 4.01 | 0.4123 | 43.01 | 10.03 | 5.97 | 6.90 | 10.15 | -8.89 | 10.35 |
ChemoMetec A/S | 45.66m | 15.26m | 803.21m | 173.00 | 53.38 | 12.87 | 46.59 | 17.59 | 7.83 | 7.83 | 23.44 | 32.48 | 0.6112 | 0.745 | 6.97 | 2,357,630.00 | 20.42 | 27.96 | 24.40 | 35.10 | 78.80 | 79.57 | 33.41 | 35.02 | 3.76 | -- | 0.0073 | 144.08 | -8.22 | 18.37 | -23.72 | 26.64 | 9.97 | -11.81 |
GVS SpA | 355.73m | 21.14m | 906.21m | 4.39k | 49.27 | 3.51 | 15.53 | 2.55 | 0.1457 | 0.1457 | 2.44 | 2.05 | 0.4303 | 2.00 | 6.16 | 97,169.86 | 2.56 | 7.35 | 3.25 | 10.82 | 55.12 | 58.74 | 5.94 | 12.44 | 1.03 | 3.98 | 0.5461 | -- | 9.58 | 15.25 | -43.37 | -9.97 | 16.08 | -- |
Biotage AB | 154.58m | 18.53m | 1.08bn | 667.00 | 59.41 | 3.92 | 33.57 | 6.98 | 3.12 | 3.12 | 26.05 | 47.36 | 0.4237 | 1.70 | 6.60 | 3,094,956.00 | 5.08 | 10.74 | 5.87 | 12.77 | 62.90 | 61.40 | 11.98 | 15.75 | 1.14 | 16.13 | 0.0628 | 40.11 | 19.54 | 15.50 | -8.21 | 7.97 | 14.05 | 1.30 |
Xvivo Perfusion AB | 51.78m | 8.95m | 1.17bn | 152.00 | 128.21 | 7.87 | 83.67 | 22.69 | 3.95 | 3.95 | 22.69 | 64.28 | 0.3441 | 1.22 | 4.48 | 4,367,031.00 | 5.95 | 1.24 | 6.45 | 1.33 | 74.16 | 73.14 | 17.28 | 4.76 | 3.27 | -- | 0.0133 | 0.00 | 43.88 | 26.04 | 398.29 | 48.57 | 21.35 | -- |
Oxford Nanopore Technologies PLC | 167.75m | -159.06m | 1.36bn | 1.24k | -- | 2.48 | -- | 8.09 | -0.187 | -0.187 | 0.197 | 0.662 | 0.2265 | 0.7333 | 2.86 | 135,499.20 | -21.47 | -21.12 | -24.63 | -24.67 | 53.89 | 53.90 | -94.82 | -81.85 | 3.36 | -- | 0.0747 | -- | -14.57 | 39.15 | -69.74 | -- | 8.92 | -- |
Embla Medical hf | 612.83m | 45.68m | 1.46bn | 4.00k | 32.41 | 2.63 | 17.18 | 2.39 | 0.9514 | 0.9514 | 12.75 | 11.74 | 0.5639 | 2.20 | 6.40 | 1,368,948.00 | 4.21 | 4.06 | 4.97 | 4.76 | 61.80 | 62.47 | 7.47 | 6.91 | 1.12 | 5.54 | 0.4205 | 3.99 | 9.33 | 5.09 | 37.34 | -6.05 | 6.50 | -- |
SKAN Group AG | 306.01m | 28.68m | 1.62bn | 1.42k | 55.50 | 10.29 | 39.25 | 5.29 | 1.43 | 1.43 | 15.24 | 7.70 | 0.9179 | 0.6845 | 12.01 | 247,846.50 | 9.03 | 7.56 | 18.78 | 14.95 | 74.07 | 73.24 | 9.84 | 9.63 | 0.5813 | 38.46 | 0.0341 | 24.09 | 15.55 | 118.77 | 38.59 | 35.49 | -- | -- |
Elekta AB (publ) | 1.34bn | 83.96m | 1.77bn | 4.57k | 24.51 | 2.59 | 10.33 | 1.32 | 2.96 | 2.96 | 47.38 | 28.01 | 0.5822 | 3.16 | 2.89 | 3,903,469.00 | 3.65 | 4.19 | 6.53 | 7.51 | 36.76 | 39.03 | 6.27 | 7.37 | 0.7425 | 3.91 | 0.4196 | 68.60 | 7.41 | 5.98 | 38.07 | 1.68 | 20.06 | 5.92 |
Holder | Shares | % Held |
---|---|---|
Baillie Gifford & Co.as of 11 May 2023 | 41.71m | 4.77% |
Storebrand Asset Management ASas of 01 Jul 2024 | 35.29m | 4.04% |
Invesco Advisers, Inc.as of 28 Feb 2023 | 28.66m | 3.28% |
Lansdowne Partners (UK) LLPas of 28 Feb 2023 | 28.00m | 3.20% |
GIC Pte Ltd. (Investment Management)as of 27 Mar 2024 | 25.70m | 2.94% |
Redmile Group LLCas of 28 Feb 2023 | 24.70m | 2.83% |
Morgan Stanley Smith Barney LLC (Investment Management)as of 01 Jul 2024 | 17.17m | 1.97% |
The Vanguard Group, Inc.as of 01 Jul 2024 | 13.12m | 1.50% |
Aberforth Partners LLPas of 01 Jul 2024 | 11.13m | 1.27% |
Norges Bank Investment Managementas of 01 Jul 2024 | 8.35m | 0.96% |